We are pleased to release the State of the U.S. Life Sciences Market report, which includes an overview of activity across the sector, including funding, talent growth, the effects of policy changes and more. As the industry adjusts to new economic realities and shifting priorities, companies are exploring new ways to optimize operations, manage costs and position themselves for long-term growth.
Key Takeaways:
- Expected NIH funding cuts could force research institutions to reallocate budgets or scale back activity, further dampening demand for life sciences space.
- Life sciences companies face shrinking budgets and are turning to cost effective strategies to stretch their resources, such as using shared coworking labs, relocating to lower cost markets and consolidating or subleasing space.
- In the first half of 2025, life sciences venture capital (VC) funding reached $20.8 billion, 44.9% of 2024’s total and is on track to surpass pre-pandemic levels.
- Development activity has declined dramatically, even in top life sciences clusters, as pandemic-era projects deliver into an already saturated market.
- To address pressure on drug pricing and access, companies are investing in research and development (R&D) and acquisitions to lower costs and improve affordability, reflecting a broader push to expand innovation while balancing profit and patient access.
- High rents in hubs like Boston-Cambridge, the Bay Area, and San Diego are pushing companies toward lower-cost markets with strong talent, top universities and tax incentives for expansion.